JYNT vs. CRDF, VERU, ATOS, AKYA, INMB, ALIM, PROF, MASS, ABOS, and SMLR
Should you be buying Joint stock or one of its competitors? The main competitors of Joint include Cardiff Oncology (CRDF), Veru (VERU), Atossa Therapeutics (ATOS), Akoya Biosciences (AKYA), INmune Bio (INMB), Alimera Sciences (ALIM), Profound Medical (PROF), 908 Devices (MASS), Acumen Pharmaceuticals (ABOS), and Semler Scientific (SMLR). These companies are all part of the "medical" sector.
Cardiff Oncology (NASDAQ:CRDF) and Joint (NASDAQ:JYNT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.
In the previous week, Cardiff Oncology had 1 more articles in the media than Joint. MarketBeat recorded 2 mentions for Cardiff Oncology and 1 mentions for Joint. Cardiff Oncology's average media sentiment score of 0.00 beat Joint's score of -0.50 indicating that Joint is being referred to more favorably in the news media.
16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 76.9% of Joint shares are owned by institutional investors. 6.3% of Cardiff Oncology shares are owned by company insiders. Comparatively, 4.0% of Joint shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Cardiff Oncology has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Joint has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.
Cardiff Oncology presently has a consensus target price of $10.50, indicating a potential upside of 157.99%. Joint has a consensus target price of $21.50, indicating a potential upside of 75.80%. Given Joint's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cardiff Oncology is more favorable than Joint.
Joint received 240 more outperform votes than Cardiff Oncology when rated by MarketBeat users. Likewise, 62.25% of users gave Joint an outperform vote while only 61.67% of users gave Cardiff Oncology an outperform vote.
Joint has a net margin of -8.19% compared to Joint's net margin of -8,492.01%. Cardiff Oncology's return on equity of 7.80% beat Joint's return on equity.
Joint has higher revenue and earnings than Cardiff Oncology. Joint is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Joint beats Cardiff Oncology on 10 of the 18 factors compared between the two stocks.
Get Joint News Delivered to You Automatically
Sign up to receive the latest news and ratings for JYNT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JYNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
